Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.

Zweegman S, Stege CAM, Haukas E, Schjesvold FH, Levin MD, Waage A, Leys RBL, Klein SK, Szatkowski D, Axelsson P, Hieu Do T, Knut-Bojanowska D, van der Spek E, Svirskaite A, Klostergaard A, Salomo M, Blimark C, Ypma PF, Mellqvist UH, Poddighe PJ, Stevens-Kroef M, van de Donk NWCJ, Sonneveld P, Hansson M, van der Holt B, Abildgaard N

Open source

DOI: 10.3324/haematol.2019.240374
Published: 2020 Dec 1
Container: Haematologica
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2019.240374,
  title = {Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.},
  author = {Zweegman S and Stege CAM and Haukas E and Schjesvold FH and Levin MD and Waage A and Leys RBL and Klein SK and Szatkowski D and Axelsson P and Hieu Do T and Knut-Bojanowska D and van der Spek E and Svirskaite A and Klostergaard A and Salomo M and Blimark C and Ypma PF and Mellqvist UH and Poddighe PJ and Stevens-Kroef M and van de Donk NWCJ and Sonneveld P and Hansson M and van der Holt B and Abildgaard N},
  year = {2020},
  journal = {Haematologica},
  doi = {10.3324/haematol.2019.240374},
  url = {https://doi.org/10.3324/haematol.2019.240374}
}

RIS

TY  - JOUR
TI  - Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.
AU  - Zweegman S
AU  - Stege CAM
AU  - Haukas E
AU  - Schjesvold FH
AU  - Levin MD
AU  - Waage A
AU  - Leys RBL
AU  - Klein SK
AU  - Szatkowski D
AU  - Axelsson P
AU  - Hieu Do T
AU  - Knut-Bojanowska D
AU  - van der Spek E
AU  - Svirskaite A
AU  - Klostergaard A
AU  - Salomo M
AU  - Blimark C
AU  - Ypma PF
AU  - Mellqvist UH
AU  - Poddighe PJ
AU  - Stevens-Kroef M
AU  - van de Donk NWCJ
AU  - Sonneveld P
AU  - Hansson M
AU  - van der Holt B
AU  - Abildgaard N
PY  - 2020
JO  - Haematologica
DO  - 10.3324/haematol.2019.240374
UR  - https://doi.org/10.3324/haematol.2019.240374
ER  -

APA

S, Z., CAM, S., E, H., FH, S., MD, L., A, W., RBL, L., SK, K., D, S., P, A., T, H. D., D, K., E, V. D. S., A, S., A, K., M, S., C, B., PF, Y., UH, M., PJ, P., M, S., NWCJ, V. D. D., P, S., M, H., B, V. D. H., & N, A. (2020). Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.. Haematologica. https://doi.org/10.3324/haematol.2019.240374

Source records

pubmed · retrieved 2026-09-26T11:16:29.891Z